User Tools

Site Tools

Trace:
basics:start

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
basics:start [2026/02/12 20:54] – andrew2393cnsbasics:start [2026/02/12 21:11] (current) – [High-Yield Framework] andrew2393cns
Line 18: Line 18:
 ---- ----
  
 +===== High-Yield Framework =====
 +
 +  * Innate immunity initiates inflammation.
 +  * Adaptive immunity provides specificity and memory.
 +  * Th1/Th17 drive autoimmune inflammation.
 +  * Th2 drives allergic disease.
 +  * COX pathway → prostaglandins.
 +  * 5-LOX pathway → leukotrienes.
 +  * NSAIDs block COX.
 +  * COX-2 inhibitors selectively block inflammatory COX-2.
 +  * Leukotriene modifiers block bronchoconstrictive leukotrienes.
 +  * Corticosteroids suppress upstream inflammatory transcription.
 +  * Biologics target specific cytokines.
 +
 +----
 ===== I. Core Immune Physiology ===== ===== I. Core Immune Physiology =====
  
Line 48: Line 63:
   * Th1 → [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]   * Th1 → [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]
   * Th2 → [[allergy:clinical:allergic_rhinitis|Allergic Disease]] / [[respiratory:clinical:asthma|Asthma]]   * Th2 → [[allergy:clinical:allergic_rhinitis|Allergic Disease]] / [[respiratory:clinical:asthma|Asthma]]
-  * Th17 → [[dermatology:clinical:psoriasis|Psoriasis]] / [[gastroenterology:clinical:inflammatory_bowel_disease|IBD]]+  * Th17 → [[dermatology:clinical:psoriasis|Psoriasis]] / [[gastroenterology:clinical:ibd|IBD]]
   * Treg → immune tolerance   * Treg → immune tolerance
  
Line 76: Line 91:
  
   * [[respiratory:clinical:asthma|Asthma]]   * [[respiratory:clinical:asthma|Asthma]]
-  * [[gastroenterology:clinical:inflammatory_bowel_disease|IBD]]+  * [[gastroenterology:clinical:ibd|IBD]]
   * [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]   * [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]
   * [[dermatology:clinical:psoriasis|Psoriasis]]   * [[dermatology:clinical:psoriasis|Psoriasis]]
Line 129: Line 144:
 Drug modulation: Drug modulation:
  
-  * [[allergy:drugs:second_generation_antihistamines|Second Generation Antihistamines]] +  * [[allergy:drug_classes:first_generation_h1|First Generation Antihistamines]] 
-  * First-generation antihistamines+  * [[allergy:drug_classes:second_generation_h1|Second Generation Antihistamines]]
   * [[endocrine:drug_classes:corticosteroids|Corticosteroids]]   * [[endocrine:drug_classes:corticosteroids|Corticosteroids]]
   * Epinephrine   * Epinephrine
Line 141: Line 156:
 ---- ----
  
-==== Complement Cascade =====+==== Complement Pathway =====
  
-  * [[immunology:complement_system|Complement System]] +Drug Modulation
- +
-Drug modulation:+
  
-  * [[immunology:complement_inhibitors|Complement Inhibitors]]+  * [[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]]
  
 ---- ----
Line 173: Line 186:
 ==== Targeted Immune Therapies ==== ==== Targeted Immune Therapies ====
  
-===== [[immunology:biologics:anti_tnf_agents|Anti-TNF Agents]] =====+[[immunology:biologics:anti_tnf_agents|Anti-TNF Agents]]
  
   * [[immunology:biologics:infliximab|Infliximab]]   * [[immunology:biologics:infliximab|Infliximab]]
Line 183: Line 196:
 ----- -----
  
-===== [[immunology:biologics:anti_il_12_23_agents|Anti-IL-12/23 Agents]] =====+[[immunology:biologics:anti_il_12_23_agents|Anti-IL-12/23 Agents]]
  
   * [[immunology:biologics:ustekinumab|Ustekinumab]]   * [[immunology:biologics:ustekinumab|Ustekinumab]]
Line 189: Line 202:
 ----- -----
  
-===== [[immunology:drug_classes:il_23_inhibitors|IL-23 Inhibitors]] =====+[[immunology:drug_classes:il_23_inhibitors|IL-23 Inhibitors]]
  
   * [[immunology:biologics:guselkumab|Guselkumab]]   * [[immunology:biologics:guselkumab|Guselkumab]]
Line 198: Line 211:
 ----- -----
  
-===== [[immunology:drug_classes:il_17_inhibitors|IL-17 Inhibitors]] =====+[[immunology:drug_classes:il_17_inhibitors|IL-17 Inhibitors]]
  
   * [[immunology:biologics:secukinumab|Secukinumab]]   * [[immunology:biologics:secukinumab|Secukinumab]]
Line 207: Line 220:
 ----- -----
  
-===== [[immunology:drug_classes:il_6_inhibitors|IL-6 Inhibitors]] =====+[[immunology:drug_classes:il_6_inhibitors|IL-6 Inhibitors]]
  
   * [[immunology:biologics:tocilizumab|Tocilizumab]]   * [[immunology:biologics:tocilizumab|Tocilizumab]]
Line 215: Line 228:
 ----- -----
  
-===== [[immunology:drug_classes:il_1_inhibitors|IL-1 Inhibitors]] =====+[[immunology:drug_classes:il_1_inhibitors|IL-1 Inhibitors]]
  
   * [[immunology:biologics:anakinra|Anakinra]]   * [[immunology:biologics:anakinra|Anakinra]]
Line 223: Line 236:
 ----- -----
  
-===== [[immunology:drug_classes:anti_ige_agents|Anti-IgE Agents]] =====+[[immunology:drug_classes:anti_ige_agents|Anti-IgE Agents]]
  
   * [[immunology:biologics:omalizumab|Omalizumab]]   * [[immunology:biologics:omalizumab|Omalizumab]]
Line 229: Line 242:
 ----- -----
  
-===== [[immunology:biologics:anti_integrin_agents|Anti-Integrin Agents]] =====+[[immunology:biologics:anti_integrin_agents|Anti-Integrin Agents]]
  
   * [[immunology:biologics:vedolizumab|Vedolizumab]]   * [[immunology:biologics:vedolizumab|Vedolizumab]]
Line 236: Line 249:
 ----- -----
  
-===== [[immunology:drug_classes:jak_inhibitors|JAK Inhibitors]] =====+[[immunology:drug_classes:jak_inhibitors|JAK Inhibitors]]
  
   * [[immunology:drugs:tofacitinib|Tofacitinib]]   * [[immunology:drugs:tofacitinib|Tofacitinib]]
Line 246: Line 259:
 ----- -----
  
-===== [[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]] =====+[[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]]
  
   * [[immunology:biologics:eculizumab|Eculizumab]]   * [[immunology:biologics:eculizumab|Eculizumab]]
Line 255: Line 268:
 ----- -----
  
-===== [[immunology:drug_classes:costimulation_blockers|Costimulation Blockers]] =====+[[immunology:drug_classes:costimulation_blockers|Costimulation Blockers]]
  
   * [[immunology:biologics:abatacept|Abatacept]]   * [[immunology:biologics:abatacept|Abatacept]]
  
-===== High-Yield Framework ===== 
- 
-  * Innate immunity initiates inflammation. 
-  * Adaptive immunity provides specificity and memory. 
-  * Th1/Th17 drive autoimmune inflammation. 
-  * Th2 drives allergic disease. 
-  * COX pathway → prostaglandins. 
-  * 5-LOX pathway → leukotrienes. 
-  * NSAIDs block COX. 
-  * COX-2 inhibitors selectively block inflammatory COX-2. 
-  * Leukotriene modifiers block bronchoconstrictive leukotrienes. 
-  * Corticosteroids suppress upstream inflammatory transcription. 
-  * Biologics target specific cytokines. 
basics/start.1770929651.txt.gz · Last modified: by andrew2393cns